Search for Clinical Trial Results

Sponsored By

Carcinoma, Endometrioid - 25 Studies Found

Status Study
Completed Study Name: POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus
Condition:
  • Carcinoma, Endometrioid
  • mTOR Protein

Date: 2014-02-11
Interventions: Drug: Temsirolimus Other Name: Torisel
Not yet recruiting Study Name: Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
Condition:
  • Grade 1 Endometrial Endometrioid Adenocarcinoma
  • Grade 2 Endomet
    Date: 2017-01-11
    Interventions:
    • Drug: Entinostat Given PO
Withdrawn Study Name: PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion
Condition: Ovarian Cancer
Date: 2005-09-12
Interventions: Procedure: immunohistochemical, methylation, gene transfection
Recruiting Study Name: Improving the Treatment for Women With Early Stage Cancer of the Uterus
Condition:
  • Complex Endometrial Hyperplasia With Atypia
  • Grade 1 Endometrial Endome
    Date: 2012-09-12
    Interventions:
    • Drug: Levonorgestrel Intrauter
Active, not recruiting Study Name: The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy
Condition:
  • Grade 1 Endometrial Endometrioid Adenocarcinoma
  • Grade 2 Endomet
    Date: 2014-12-22
    Interventions:
    • Drug: Depot medroxyprogesterone acetate

Completed Study Name: Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma
  • Other: Laboratory Biomarker Analysis

Withdrawn Study Name: Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
Condition:
  • Endometrioid Carcinoma
  • Clear Cell Carcinoma
  • Endometrial Endometrioid Adenocarcinoma
  • Endometrial Mixed Adeno
    Date: 2016-03-30
    Interventions:
    • Drug: Copanlisib Given IV
Completed Study Name: Mifepristone for Patients With Endometrial Cancer and LGESS
Condition: Endometrial Cancer
Date: 2007-07-19
Interventions: Drug: Mifepristone 200 mg by mouth (PO) Daily x 4 Weeks
Active, not recruiting Study Name: Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Condition:
  • Fallopian Tube Endometrioid Adenocarcinoma
  • Fallopian Tube Mucin
    Date: 2010-07-21
    Interventions:
    • Biological: Bevacizumab Given

Next >>>